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Background: Breast cancer is rarely diagnosed in very young women (35years old or younger), and it often
presents with distinct clinical-pathological features related to a more aggressive phenotype and worse prognosis
when diagnosed at this early age. A pending question is whether breast cancer in very young women arises from
the deregulation of different underlying mechanisms, something that will make this disease an entity differentiated
from breast cancer diagnosed in older patients.
Methods: We performed a comprehensive study of miRNA expression using miRNA Affymetrix2.0 array on paraffin-
embedded tumour tissue of 42 breast cancer patients 35 years old or younger, 17 patients between 45 and 65 years
old and 29 older than 65 years. Data were statistically analyzed by t-test and a hierarchical clustering via average
linkage method was conducted. Results were validated by qRT-PCR. Putative targeted pathways were obtained
using DIANA miRPath online software.
Results: The results show a differential and unique miRNA expression profile of 121 miRNAs (p-value <0.05), 96 of
those with a FDR-value <0.05. Hierarchical clustering grouped the samples according to their age, but not by
subtype nor by tumour characteristics. We were able to validate by qRT-PCR differences in the expression of 6 miRNAs:
miR-1228*, miR-3196, miR-1275, miR-92b, miR-139 and miR-1207. Moreover, all of the miRNAs maintained the
expression trend. The validated miRNAs pointed out pathways related to cell motility, invasion and proliferation.
Conclusions: The study suggests that breast cancer in very young women appears as a distinct molecular
signature. To our knowledge, this is the first time that a validated microRNA profile, distinctive to breast cancer in
very young women, has been presented. The miRNA signature may be relevant to open an important field of
research in order to elucidate the underlying mechanism in this particular disease, which in a more clinical setting,
could potentially help to identify therapeutic targets in this particular set of patients.
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Breast cancer (BC) is the most common cancer in women
worldwide. It is estimated that breast cancer will account
for up to 29% of all new cases of cancer in women in the
USA in 2013 [1]. Although the median age at onset is
61 years, approximately one in forty women diagnosed
with early breast cancer is very young, constituting 5 to
7% of all cancer deaths in these women [2,3].* Correspondence: gribasdespuig@gmail.com
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article, unless otherwise stated.Breast cancer in very young women is typically more
aggressive than in their older counterparts, in part owing
to the over-representation of high-grade, triple-negative
tumours in the former patients. Indeed, very young
patients diagnosed with breast cancer usually present
larger and poorly differentiated tumours, lymph node
invasion, HER2 overexpression and an absence of hor-
mone receptor (HR) expression [4,5]. It is still a matter
of controversy, however, as to whether breast cancer in
very young patients (BCVY) is a biologically unique en-
tity that should be considered separately or if its behav-
iour and outcome is solely due to the higher frequencytral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.biomedcentral.com/1471-2407/14/529of more aggressive subtypes. There are contradictory
studies on the identification of young age as an inde-
pendent prognostic factor [5-7].
MicroRNAs (miRNAs) are post-transcriptional regula-
tors that bind to complementary sequences on target
messenger RNA transcripts (mRNAs), usually resulting
in translational repression or target degradation and gene
silencing [8-10]. Deregulation of many of the miRNA’s
expression has been linked to various types of disease
[11-13]; (http://www.mir2disease.org/). The expression
of several miRNAs has been found to be deregulated in
some types of cancer [14,15]. High levels of some miRNA
have been linked to stem cell promotion [16-18], while
others exhibit a reduced expression of many, promoting
loss of differentiation [19,20]. Both are common traits
in tumour development, but many other unknown
underlying mechanisms could be affected [21]. More-
over, miRNA expression profiling has been previously
shown to be a useful tool for classifying different cancer
risk stratification, outcome prediction and classification
of histological subtypes [22,23]. Regarding breast can-
cer, several studies have identified molecular markers,
such as miR-21, miR-9, let-7, miR-205, miR-200 family,
miR-126 and miR-335, which correlate to tumours of
high metastatic and proliferative capacity, larger size
and thus poorer prognosis [18,24-29].
As previously stated, very little is known about the
biology of BCVY, and published studies have focused
mainly on hereditary tumours and genomic traits [30,31].
Nevertheless, the data from two previous published stud-
ies point to the possibility that BCVY could have a distinct
molecular identity [32,33].
We performed a study with the aim to identify whether
BCVY had a different miRNA profile compared with older
age. A secondary objective was to identify those miRNA
that are typically up- or downregulated in the tumours
from very young patients, which could reveal the ongoing
mechanisms of the development of the tumour and of its
aggressiveness at an early age.
Methods
Sample selection
Tissue samples were obtained from patients undergo-
ing surgery for breast cancer at the Hospital Clinico
Universitario of Valencia from among the Spanish
population. As shown in Figure 1, we selected two
groups of women according to their age, one group of
women 35 years old or younger (BCVY), and the other
of those older than 65 years of age. After excluding
those samples with known BRCA1/2 mutation, we got
a total of 148 women 35 years old or younger and 3140
patients over 65 years of age with an available biopsy
sample before any treatment. We screened for BRCA1/2
status according to the ESMO Guidelines for HereditaryBreast Cancer that follow standard criteria for high-risk
patients and from those, we excluded the positive cases
from our study as well as those with known or suspected
family history of breast cancer. All the participants, with
one exception, were Caucasian women of European origin
and gave written, informed consent by signing an ap-
proved Biobank document allowing research use of the
remaining diagnostic tumour material. The study was ap-
proved by the Institutional Health Incliva-Hospital Clinico
Ethics Committee.
After evaluating the quantity and quality of the mater-
ial, a total of 33 breast cancer patients were included in
this study: 21 women diagnosed before the age of 35 cat-
egorized as the BCVY group, and 12 breast cancer pa-
tients older than 65 years old and matched by tumour
subtype (Table 1). We also collected tissue samples from
three young cancer-free women undergoing mammary
reduction surgery, with ages 28, 34 and 40 years old, and
BMI within normal values (between 20 and 24).
For the validation set, we included a total of 55 new
independent samples from HCUV, selected with the
same aforementioned criteria, 21 of which were BCVY
patients, 17 were older than 65 years, and 17 individuals
were post-menopausal women between 45 and 65 years
old. We included this new age group in order to better
establish the cut-off age of the miRNA profile. Overall,
the present study was performed on a total of 88 breast
cancer patients.
All of the tissue samples were biopsied from primary
tumour and locked in FFPE (Formalin-fixed paraffin-
embedded). Three-μm thick paraffin sections were stained
with haematoxylin and eosin (H&E) in order to obtain a
histological control of all samples. All tissue samples con-
tained >30% tumour material. Tumour grade was assessed
based on Bloom-Richardson scoring system. Images of the
sample’s tissues can be seen in Additional file 1.
To obtain the molecular characteristics of the tumour,
presence of molecular markers ER, PR, HER2 and Ki67
was evaluated following the ACO/CAP guidelines. ER
and PR status were obtained by IHC staining and HER2
Immunohistochemical staining on TMA sections was
performed by the EnVision method with a heat-induced
antigen retrieval step. Staining results were assessed by a
pathologist. ER and PR were scored based on two-stage
scoring system: positive (1) for >10% of ER/PR positive
cells and negative (0) for less than 10%, as described pre-
viously. Proliferation was assessed measuring percentage
of Ki-67 expression. HER2 was called positive either by
detection of ERBB2 gene amplification by FISH analysis
and/or 3+ staining by DAKO system on HercepTestTM.
Where duplicate cores gave discordant results, the higher
score was used. Breast cancer tumours were classified into
four subtypes based on IHC-model (Tang P. et al., 2009)
as: luminal A (ER + and/or PR+, HER2−, Ki67 < 14%);
Figure 1 Flow diagram representing the guidelines followed in the selection of the patients suitable for the present study.
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Negative (ER−, PR−, HER2−) and HER2 overexpressed/
amplified (ER−, PR−, HER2+), plus an additional group
Luminal/HER2 (ER + and/or PR+, HER2+).
RNA isolation
Total RNA was isolated using RecoverAll Total Nucleic
Acid Isolation Kit (Applied Biosystems by Life Technolo-
gies, Carlsbad, California, USA) following the manufac-
turer’s protocol. RNA concentration was measured using a
NanoDrop ND 2000 UV–vis Spectrophotometer (Thermo
Fisher Scientific Inc., Wilmington DE, USA).
RNA integrity determined by RIN (RNA integrity
number) value was assessed with the Agilent 2100 Bioana-
lyzer using the RNA 6000 Nano Assay (Agilent Technolo-
gies Inc., Santa Clara, CA, USA).
miRNA microarray
Microarray expression profiling was performed using
GeneChip® miRNA 2.0 Array (Affymetrix, Santa Clara,
CA, USA), containing a total of 15,644 probes, in 11
replicates, including 1100 human mature miRNA, theirprecursors, 2334 human snoRNA (small nucleolar RNA)
and scaRNA (small Cajal body-specific RNA) annotated
in the miRBase v.15 database. Hybridisation and scanning
were performed according to the Affymetrix standard
protocol, using Affymetrix Expression Console software.
The microarray dataset is publicly available at GEO
database (GSE48088) http://www.ncbi.nlm.nih.gov/geo/
info/linking.html.
Array data processing and analysis
Data passed quality controls implemented in Expression
Console software, build 1.2.0.20, and QC Tool (Affyme-
trix, Santa Clara, CA, USA). All data were normalised by
the DABG-RMA, detected above background (DABG)
Robust Multichip Average (RMA) method. We selected
1100 human miRNAs, and set as the threshold for low
expression the highest common intensity value of miRNA
from vegetable organisms (not supposed to be expressed
in humans) included in the microarray. After filtering the
data, in order to determine the differences in expression
pattern between tumours from BCVY patients and from
older ones, we carried out differential expression analyses
Table 1 Clinical tumour characteristics of the sample groups used in the present study
Discovery set N = 34 (%) Validation set N = 55 (%)
Age group <35 (n = 22)* >65 (n = 12) <35 (n = 21) 45-65 (n = 17) >65 (n = 17)
Age mean (SD) 31.41 (4.04) 73.3 (10.18) 31.4 (2.87) 56.94 (5.58) 69.4 (4.48)
BMI mean (SD) 21.98 (3.53) 29.44 (6.66) 23.95 (5.50) 30.15 (8.04) 30.23 (6.55)
Histological grade
I 1 (4.55) 3 (25.00) 3 (14.29) 8 (47.06) 3 (17.65)
II 8 (36.36) 3 (25.00) 7 (33.33) 5 (29.41) 12 (70.59)
III 13 (59.09) 6 (50.00) 11 (52.38) 4 (23.53) 2 (11.76)
Histological Type
Ductal 19 (86.36) 11 (91.67) 19 (90.48) 13 (76.47) 12 (70.59)
Lobular 0 (0.00) 0 (0.00) 1 (4.76) 0 (0.00) 2 (11.76)
Others 3 (13.64) 1 (8.33) 1 (4.76) 4 (23.53) 3 (17.65)
Tumour size
< 2 cm 3 (13.64) 9 (75.00) 3 (14.29) 11 (4.71) 14 (82.35)
2-5 cm 15 (68.18) 2 (16.67) 15 (71.43) 6 (35.29) 3 (17.65)
> 5 cm 4 (18.18) 1 (8.33) 3 (14.29) 0 (0.00) 0 (0.00)
Nodal status
Positive 10 (45.45) 4 (33.33) 7 (33.33) 6 (35.29) 3 (17.65)
Negative 12 (54.55) 8 (66.67) 14 (66.67) 11 (64.71) 14 (82.35)
Receptors
ER+ 17 (77.27) 9 (75.00) 14 (66.67) 14 (82.35) 14 (82.35)
ER - 5 (22.73) 3 (25.00) 7 (33.33) 3 (17.65) 3 (17.65)
PR+ 15 (68.18) 7 (58.33) 14 (66.67) 13 (76.47) 13 (76.47)
PR - 7 (31.82) 5 (41.67) 7 (33.33) 4 (23.53) 4 (23.53)
HER2+ 10 (45.45) 3 (25.00) 5 (23.81) 2 (11.76) 2 (11.76)
HER2 - 12 (54.55) 9 (75.00) 16 (76.19) 15 (88.24) 15 (88.24)
Ki67
1-14% 5 (22.73) 3 (25.00) 5 (23.81) 8 (47.06) 5 (29.41)
14-30% 8(36.36) 5 (41.67) 11 (52.38) 7 (41.18) 10 (58.82)
>30% 9 (40.91) 4 (33.33) 5 (23.81) 2 (11.76) 2 (11.76)
Histological subtype
Luminal A 5 (22.73) 3 (25.00) 3 (14.29) 8 (47.06) 5 (29.41)
Luminal B 6 (27.27) 4 (33.33) 10 (47.62) 4 (23.53) 9 (52.94)
TN 2 (9.09) 2 (16.67) 3 (14.29) 3 (17.65) 2 (11.76)
Luminal/HER2 5 (22.73) 2 (16.67) 2 (9.52) 0 (0.00) 1 (5.88)
HER2 4 (18.18) 1 (8.33) 3 (14.29) 2 (11.76) 0 (0.00)
BMI stands for Body Mass Index and is expressed in terms of kg/m2. ER: Estrogen receptor; PR: Progesterone receptor. HER2: ErbB2 receptor; +/−: presence (+) and
absence (−) of receptor overexpression. HER2 is considered positive (+) when immunohistochemical analyses show +++/+++ or ++/+++ (and FISH shows HER2
amplification). Subtypes have been categorized according to Hormonal Receptors, HER2 expression and Ki67 value. *One of the initial 22 samples younger than
35 years old, was removed from the study due to methodology QC thresholds.
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We performed a t-test by permutation testing, and
p-values were adjusted for multiple comparisons by
Benjamini & Hochberg False Discovery Rate (FDR).
Those miRNAs with a FDR p-value <0.05 were considered
statistically significant. Average linkage hierarchical clus-
tering was performed to obtain clusters of data sets, usingGene Cluster and Treeview software (http://www.eisenlab.
org/eisen/).
In order to evaluate whether the miRNA profile de-
tected was a result of age differences or if it was influenced
by confounding factors such as tumour size, histological
grade and other features characteristic of more aggressive
tumours, we performed a t-test analysis on the filtered
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of nodal status, histological grade, percentage of ki67 ex-
pression and tumour size. Data were adjusted obtaining
the correlation between miRNAs’ expression and tumour
characteristics via linear regression with R Studio (http://
www.rstudio.com/), using the remaining residuals for the
correction.
Validation by qRT-PCR
Quantitative real time-PCR (qRT-PCR) of selected miR-
NAs was performed on breast tumour tissue samples in
independent series of women younger than 35 years old,
women between 45 and 65 years old, and women older
than 65 years using TaqMan microRNA Assays (Applied
Biosystems by Life Technologies, Carlsbad, California,
USA). Normalisation was done with RNU43 snoRNA.
The data were managed using the Applied Biosystems
software RQ Manager v1.2.1. Relative expression was
calculated by using the comparative Ct method and
obtaining the fold-change value (ΔΔCt). Data analyses
were performed via GraphPad Prism v6.00. The ANOVA
test was performed, and Tukey’s test was used to correct
for multiple comparisons (p-value threshold of 0.05).
Brown-Forsythe test was used to assess the homogeneity
of the variances in the different samples groups. Finally, the
association of the validated miRNAs was adjusted by breast
cancer subtypes using RStudio (http://www.rstudio.com/).
Pathway enrichment analysis and candidate gene
searching
DIANA miRPath pathway enrichment analysis was used
to gain insight into global molecular networks and canon-
ical pathways related to differentially expressed miRNAs
(http://diana.imis.athena-innovation.gr/DianaTools/index.
php?r=mirpath/index). The software performs an enrich-
ment analysis of multiple miRNA target genes comparing
each set of miRNA targets to all known KEGG pathways.
Those pathways showing a FDR p-value <0.05 were
considered significantly enriched between classes under
comparison. We also searched for candidate genes using
Target-scan online software (http://www.targetscan.org/)
and previously published data.
Results
miRNA expression profiling in primary breast tumours
from discovery set
After initial pre-processing of 1100 miRNA expression
data, we discarded miRNAs with uniformly low expres-
sion, reducing the number of miRNA to a total of 251
hsa-miRNAs. Finally we detected 119 miRNAs differen-
tially expressed between the two groups (p-value < 0.05)
and after adjusting for FDR, 96 miRNAs remained signifi-
cant (Additional file 2). In addition, all of these miRNA’s
expression remained significantly different even aftercorrecting by possible confounding factors (tumour
size, nodal status, ki67% and histological grade), sug-
gesting that young age is an independent factor
(Additional file 3).
Mammary tissue from three cancer-free women was
included as healthy control group. When unsupervised
hierarchical clustering was performed two clearly differ-
ent two clearly different groups of samples (Figure 2).
One group included all except one of the BC tissue sam-
ples from very young women. The other group contained
all the samples from both older women and normal tissue.
We were able to identify two major nodes of differentially
regulated miRNA in the BCVY group. As shown in
Figure 2, the 52 miRNAs overexpressed in the BCVY
group can be seen clustered in the top node, 115, (cor-
relation 0.383) while the lower node, 119, shows the
67 miRNAs found to be repressed in this BCVY set of
tumours (correlation 0.102).
From the overexpressed node (node 115) we were able
to identify two differentiated sub-nodes: node 92 (correl-
ation value 0.63) and node 84 (correlation value 0.66),
that appears to be more homogenous inside each group
of patients. Within node 84 we selected sub-node 15
(correlation 0.923) including miRNAs with the highest
significant expression difference between Young vs Old
women-Normal. When scanning the repressed node 119,
we identified six interesting sub-nodes, covering most of
the node: sub-node 102 (correlation 0.582), sub-node 79
(correlation 0.667), sub-node 76 (correlation 0.678), sub-
node 63 (correlation 0.72), sub-node 54 (correlation 0.75)
and sub-node 52 (correlation 0.75). While sub-nodes 54
and 52 reached the highest correlation value, we selected
sub-node 63 for the further study, since the expression of
the whole cluster in cancer-free tissue samples was re-
markably high, and also because the BC patients showed
levels uniformly higher than the BCVY ones. MicroRNAs
from the selected sub-nodes are listed in Figure 2, and
their expression fold change and p-values are shown in
Additional file 4.
Regarding the hsa-miRNA-star (hsa-miR-92*, hsa-miR-
149* and hsa-miR-1228*), when the main form of both
miRNA species was also differentially expressed (hsa-
miR-92* and hsa-miR-149*), we selected the main form
of each miRNA (hsa-miR-92-3p and hsa-miR-149-5p) in
order to get more reliable results.
Pathway enrichment and selection of candidate miRNAs
for validation step
With the 20 selected miRNAs, composing the two most
striking sub-nodes, we performed in silico analyses and
database searches to determine which ones might be
more biologically relevant in the breast cancer context,
and eligible for validation. Considering that the miRNAs
target from small to a very large number of mRNA




Figure 2 Heatmap representing an unsupervised cluster performed according to a hierarchical clustering method centered on the median,
using differently expressed human miRNA expression values from an Affymetrix array assay. The miRNAs plotted are those which gave
significant FDR p-values after performing a t-test according to the age group of the samples. Correlation values (0–1) of different sub-nodes are shown
in the figure according to data obtained from Cluster and Treeview software. The two most correlated, overexpressed-sub-nodes are highlighted in red
(from top to bottom, sub-node 92 and sub-node 29); highlighted in green are the most correlated repressed sub-nodes (from top to bottom 102, 79,
52, 54 and 73). The selected nodes for validation are shown in pink (node 15 and node 63).
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could have a potential impact on various biological path-
ways. To asses which pathways could be affected by the
deregulation, we used DIANA miRPath v2.0. When study-
ing miRNAs from the selected sub-nodes, KEGG pathway
enrichment analysis revealed several pathways overrepre-
sented with a FDR p-value <0.05, including adhesion and
mobility related pathways (extracellular matrix-receptor
interactions, glycosaminoglycan biosynthesis, adherens
junction, focal adhesion, cell adhesion molecules, regu-
lation of actin cytoskeleton), biological proliferation-or
differentiation-related pathways relevant in cancer devel-
opment or progression (MAPK signalling, endocytosis,
axon guidance), circadian rhythm and several cardiomyop-
athies . Within the genes involved in the pathways related
with the selected miRNAs, we found many integrins,
laminins, collagen, MAPkinases, semaforins, interleukins,claudins and calmodulins, among others. More informa-
tion and FDR p-values associated with each pathway are
shown in Additional file 5.
We have finally selected 12 miRNAs (7 from the sub-
node 15 and 5 from sub-node 63) as putative candidate
targets to perform further studies according to their sig-
nificance, previous published studies, and implications in
biological pathways: hsa-miR-1275, hsa-miR-1207-5p, hsa-
miR-149*, hsa-miR-762, hsa-miR-3196, hsa-miR-1228*,
hsa-miR-92*, hsa-miR-139-5p, hsa-miR-132, hsa-miR-379,
hsa-miR-409-3p, and hsa-miR-433. Supplementary infor-
mation is available in Additional file 6.
qRT-PCR validation in an independent set of samples
We performed a validation of the 12 selected miRNAs
using qRT-PCR, on an independent set of samples with
similar characteristics as those used in the Discovery
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55 samples into three groups (21 tumours from women
younger than 35 years, 17 tumours from women aged
between 45 and 65 and finally 17 tumours from women
older than 65) (see the clinical characteristics for the en-
tire sample set in Table 1).
We did not find evidence suggesting than women
older than 65 had any differential characteristics withFigure 3 Relative expression of the validated miRNAs which have sig
with increased expression in women ≤35 years old (BCVY). B: miRNAs with
quantified using the qRT-PCR technique and calculated using the ΔΔCt me
lines mark the 10th percentile, and outliers are represented as dots. P-values a
as a correction for multiple comparisons. The top p-value represents differenc
differences between those >65 and those 45–65 (middle group, between
those 45–65 and those ≤35 (BCVY).the 45 to 65 year age group in terms of miRNA expression
(Figure 3). Six of the twelve selected miRNAs were
confirmed to have a differential expression across groups:
miR-1228* (p-value 4.73×10−5), miR-3196 (p-value
1.98×10−4), miR-1275 (p-value 2.86×10−3), miR-92b
(p-value 0.012), miR-139-5p (p-value 0.018), and miR-
1207 (p-value 0.047). After Tukey’s correction for
multiple comparisons, we obtained p-values betweennificantly different expression in BCVY tumour samples. A: miRNAs
decreased expression in BCVY. Measures of the expression were
thod. Boxes represent the sample distribution with the mean, vertical
re calculated via One-Way ANOVA, and Tukey’s method was implemented
es between those ≤35 (BCVY) and >65; the bottom-left represents
45 and 65 years old); and bottom-right, the differences between
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between BCVY samples and the other two older groups
(Figure 3). The first four values agree with an upregulation
in BCVY, while the last two, miR-92b and miR-139-5p,
were indeed downregulated in young women group
(see Figure 3 and Additional file 2). Afterward, a t-test
analysis was used to compare the BCVY group with the
two older patient groups, treating the last two as only
one group. The results obtained were the following:
miR-1228 (p-value 7.13×10−6), miR-3196 (p-value
3.23×10−5), miR-1275 (p-value 7.77×10−4), miR-92b
(p-value 2.94×10−3), miR-139-5p (p-value 6.57×10−3),
and miR-1207 (p-value 0.523). After adjusting for tumour
subtype, four of them remained statistically significant:
miR-1228 (p-value 0.0032), miR-1275 (p-value 0.0010),
miR-3196 (p-value 0.0095), miR-139 (p-value 0.0172). It is
worth mentioning that all of the other miRNAs tested did
indeed lose expression, as was expected; however, no sig-
nificant value could be obtained due to a lack of detection
sensitivity.
Putative functional implication of the validated miRNAs
In order to establish a possible underlying biological
implication with the validated deregulated miRNAs
(hsa-miR-1228*, hsa-miR-3196, hsa-miR-1275, hsa-miR-
1207-5p, hsa-miR-92b, hsa-miR-139-5p), we used online
software and miRNA databases to perform an exhaustive
search for enrichment of candidate pathways and genes.Table 2 Significantly enriched signalling pathways associated
KEGG Pathway FDR Number of
miRNAs
Putative targ
Adherens junction 1.03×10−4 4 ACTB, WASL, R




Dilated cardiomyopathy 2.23×10−3 4 ACTB, ADCY1,
CACNA2D2, IG
Lysine degradation 0.014 3 PLOD3, ASH1L
Taste transduction 0.014 4 GNG13, SCNN1
Cell adhesion molecules (CAMs) 0.035 3 NEGR1, ITGB8,
NFASC, PVRL1,












0.039 3 ACTB, DSC2, IT
CACNA1D
Wnt signaling pathway 0.041 4 PRKCA, DVL3,
PPP2R5B, JUN,
FDR refers to p-values adjusted by Benjamini & Hochberg’s False Discovery Rate. Nu
one or more genes of the pathway.Moreover, we text-mined all published studies related to
the six validated miRNAs with the terms cancer and/or
putatively target genes. We found several enriched path-
ways related to cell motility and invasion: adherens junction
(FDR p-value 1.03×10−4), glycosaminoglycan biosynthesis
(FDR p-value 2.23×10−3), cell adhesion molecules (CAMs)
(FDR p-value 0.035) and several related genes such as
integrins, claudins and cadherins. We also found enriched
pathways involved in proliferation and apoptosis: calcium
signalling (FDR p-value 0.035) and Wnt signalling (FDR
p-value 0.041) (Table 2).
Discussion
Our data lead us to think of a differentiated miRNA sig-
nature in the group of patients diagnosed at ≤35 years.
We have detected a wide range of differentially regulated
miRNAs in BCVY when compared to tumours diag-
nosed in older women and healthy breast tissue. The fact
that the older women’s miRNA profile was highly similar
to the healthy breast tissue profile (obtained from women
under 40 years old) highlights the distinctiveness of the
miRNA profile being characteristic of BCVY patients.
These differences were maintained after validation, in an
independent series of samples using a different technique,
in which controls between 45 and 65 years were included,
suggesting that our findings are consistent and not a result
of the false positives characteristic of high throughput
technologies. Although from a limited sample size, the into the validated differentially expressed miRNAs
et genes
AC2, IGF1R, PTPRF, TJP1, CDH1, CSNK2B, FARP2, PTPRJ, SSX2IP, PTPRB, PVRL1
4, CYP27B1
ITGB8, ITGB3, CACNG7, TTN, ADCY3, ITGA5, ITGB5, DMD, PRKACA, CACNA1C,
F1, CACNA2D1, CACNA1D, PRKACB
, SETD8, MLL2, MLL, SETD1A
B, GNB1, PRKACA, SCNN1A, PRKACB
MPZ, SDC3, CLDN19, CLDN11, PTPRF, CDH1, CD276, NRXN2, CD86, ICOSLG,
NLGN3
, ATP2B2, BDKRB2, ADCY3, ITPKB, SLC8A2, PDE1B, CACNA11, CAMK2A, NOS1,
1, CACNA1C, PHKA1, MYLK3, CACNA1D, GRIN2A, PRKACB, CHRM1
RAC2, PLA2G4F, ASAP3, GSN, FCGR1A, MARCKS, PIP5K1A, PLD2, AKT3, VASP,
GB3, CACNG7, TTN, ITGA5, ITGB5, DMD, CACNA1C, CACNA2D2, IGF1,
CNA1D
GB8, ITGB3, CACNG7, ITGA5, ITGB5, DMD, CACNA1C, CACNA2D2, CACNA2D1,
WNT16, ROCK1, RAC2, VANGL1, PPP2CA, PPP2R5C, CAMK2A, WNT6, PRICKLE1,
APC2, PPP2R1A, PRKACA, VANGL2, CSNK2B, WNT9A, PRKACB
mber of miRNAs is the count of miRNAs involved in the pathway and targeting
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lated to high cell proliferation, motility and invasion,
which support the fact that tumours from young woman
have an aggressive behaviour and are prone to metastasis.
Other studies in breast cancer showing miRNA profiles
characterized by bad prognosis, revealed similar signalling
deregulated pathways [34].
Recently, miRNA profiling has arisen as a major ap-
proach study technique, that aims to gain more insight
into tumour biology, and widespread deregulated miRNA
has been demonstrated in various tumour types [35]. It
has been shown that specific miRNA, such as miR-195
and let-7a, may play a role as a potential diagnostic tool
and a new biomarker for both detecting non-invasive,
early breast cancer as well as monitoring treatment effect-
iveness [36,37]. Furthermore, other studies have revealed
miRNA expression to be specific for each breast tissue
type, but it seems not to exist a specific miRNA profile
distinctive of BC subtypes, which may point to both differ-
ences in the biology of tumours, as well as to patterns of
response to treatment [38-44]. As suggested in previous
studies, our results reinforce the applicability of the study
of miRNA expression in FFPE samples, since the small
size of the miRNA preserves them from degradation [45].
In addition, the use of Taq-Man-assay for microRNA ex-
pression profiling and validation in FFPE breast tissue
samples is reported to offer excellent inter-experimental
reproducibility and biological accuracy [41,46].
Several studies confirm that BC in very young patients
is a more aggressive disease given the high frequency of
adverse prognosis factors or more aggressive subtypes at
this age [4]. In most studies published the cut-off age for
defining young women is 45 years. However, results
from a large Korean breast cancer study with 9885 pre-
menopausal patients detects a sharp increase in risk of
death from breast cancer in women younger than 35 years
old, establishing this age as the more reasonable cut-off
defining young age-onset breast cancer [47]. Following
this recommendation, we have determined 35 years old as
the threshold for the young group, since we considered
that, despite this cut-off makes harder patient’s recruit-
ment within the young age group, it identifies a more
homogeneous population.
Whether breast cancer in the young is a distinct bio-
logical entity or just a reflection of a higher percentage
of cases with aggressive phenotypes (that are otherwise
indistinctive from aggressive tumours in older pa-
tients) remains a matter of controversy and an import-
ant outstanding question with possible therapeutic
implications [6].
In order to minimize clinical-pathological putative con-
founding effects, we have performed several comparisons
in the expression of these miRNA in terms of tumour
size, axillary node involvement, histological grade andki67, with the results showing no significant differences.
This absence of significant differences, having considered
the most relevant adverse prognostic factors, suggests that
young age could be indeed a factor independent of
subtype, size, nodal involvement, or proliferative char-
acteristics that merits further study.
Moreover, no distinct therapy is considered for young
or very young patients, but in many cases these patients
are over-treated as a consequence of their young age. Thus
identification of new prognostic or diagnostic platforms
and identification of specific targets is needed for this
subgroup [48].
Data about genomic profile in young breast cancer pa-
tients are scarce in the literature; however, Colak and cols.
have recently published an age-specific gene expression
signature in breast cancer [33]. Although, the study fo-
cused on women younger than 45, it also included 6 sam-
ples from those younger than 35 (BCVY). The study
pointed to genes barely implicated in the pathways found
in our study. That notwithstanding, the authors proposed
that there is a different molecular profile characterizing
breast cancer in very young women.
A recent retrospective study analysed data from 20
data sets and assessed the role of these genetic signa-
tures in predicting the prognosis in breast cancer in
young women. This study confirmed that BC patients
aged 40 or less were diagnosed more frequently with
oestrogen receptors and HER2 negative tumours. Fur-
thermore, although proliferation-related gene signatures
were not associated with age in this study, in two inde-
pendent cohorts BC in younger patients was associated
with immature epithelial cell and growth factor signal-
ling pathways, leading to the conclusion that BC in
young women seems to be a distinct entity beyond the
intrinsic breast cancer subtype classification [32].
The data obtained with our miRNA profiling supports
the evidence proposed by Yau and cols that could be de-
tected an age-dependent signature in BC with a number
of samples from young women very similar to ours. Al-
though the conclusions are raised on gene expression
analyses the signaling pathways detected including cell
cycle, mammary gland development and extracellular
matrix (ECM) are also highlighted in our study [49].
In our study, the most significantly set of deregulated
miRNAs in BCVY pointed out to pathways related to
apoptosis, cell motility, proliferation, mitotic regulatory
processes and the PI3K and IGFR transduction that confer
tumours high metastatic capacity, increasing progression
and invasion (Table 3). Furthermore, many of the path-
ways involved include integrins and laminins as target
genes, described as proliferation genes portraits of breast
tumours [50].
If we take into account the set of validated miRNAs
(upregulated miR-1228*, miR-3196, miR-1275, miR-1207
Table 3 Published information about validated microRNA target genes and implication in cancer
miRNAs Gene Target/Function Published papers
miR-1228 MOAP1 Bcl homologous. When repressed, allows cells to escape
from apoptosis.
Yan et al. Apoptosis. 2012 [69]
miR-3196 PAX2, THTPA,
PIK3R2, BBC3
PAX2. Implicated in suppression of translation (through
WT1). Associated to low breast cancer risk. Repression of
PAX2 would promote a more aggressive breast cancer.
THTPA. Metastasis tumour suppressor. PIK3R2. Proliferation
pathway. Anti-apoptotic. BBC3. Pro-apoptotic gene and
associated to tumour size.
Beauchemin et al. Molecular Cancer. 2011 [53]. Kovacevic
et al. Biochem Biophys Acta. 2008 [58]. Tajnik et al. Cancer
Biomarkers. 2012 [66]. Wong et al. PlosOne. 2012 [68]
miR-1275 IGF1, NFIX,
Claudin11
IGF1 related to tumour proliferation. NFIX hypermethylated
in breast cancer lines. Claudin 11, cellular adhesion
molecule, associated to invasion and capacity of metastasis
when downregulated.
Castaño et al. Cancer Discovery. 2013 [54]. Awsare,et al.
Oncology reports. 2011 [51]. Webb et al. BMC Cell Biol. 2013
[67]. Özata et al. Endocr Relat Cancer .2011 [62]. Lian et al. Int J
Oncol. 2012 [60]. Katsushima et al. J Biol. Chem. 2012 [57]
miR-1207 DHCR24,
Claudins
DHCR24 expression decreased in metastatic prostate cancer.
Claudins. Associated with cell motility and tumour invasion
and spread of tumour cells and metastasis.
Romanuik et al. Am J Pathol. 2009 [64]. Webb et al. BMC




RAP1B, family RAS (oncogene). It has a pseudogene. IGF1R
Low expression of miR in colo-rectal cancer is associated to
more advanced tumours and less survival. FOS proteins are
implicated in cell cycle, differentiation and cellular
transformation. Dowregulation induces increase in apoptosis
and more cellular differentiation. TOP2A, topoisomerase.
Upregulation is associated to tumour proliferation. CXCR4,
associated with progression and metastasis in CRC.
Regulated by HER2-CD44 via miR139.
Guo et al. Cell Biology. 2012 [56]. Milde-Langosch et al.
Breast Cancer Res Treat. 2013 [61]. Shen et al. Biochemical
Pharmacology. 2012 [65]. Fan et al. Cell Biochem Funct.
2012 [55]. Bao et al. Gastroenterology. 2011 [52]
miR-92b PSMD10,
FOX2
PSMD10. Inhibition of the protein will slow down tumour
progression in hepatocarcinoma. High increased expression
related to worse prognostic in glioma. FOX2. RNA-binding
protein regulates alternative splicing.
Leidner et al. PlosOne. 2013 [59]. He et al. Nature. 2005 [15].
Qian et al. Gastroenterology. 2012 [63]
Genes targeted by miRNAs were obtained neither via in silico predictions with Targetscan or searching for previously experimental published works. Most relevant
genes are included in the table and most interesting cancer-related pathways or mechanisms has been added to function column.
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able to detect in the literature their implications in escap-
ing of apoptosis and therefore, contributing to migration
and invasion [15,51-69]. Downregulation of one particular
miRNA, miR-139, might promote gastric tumour progres-
sion and metastasis via upregulating CXCR4, Bao and cols
suggest that miR-139 might be suppressed by upstream
HER2 signaling, a strongly deregulated pathway in breast
cancer [52].
We cannot fully reject an influence of demographics
or epidemiological factors inherent to young women in
the tumour profile obtained. Bearing this in mind, we
believe that the inclusion of healthy young breast tissue
in the analysis might have minimized these putative con-
founding epidemiologic aspects.
Oestrogen levels are an age-dependent factor increas-
ing the risk of breast cancer, which can themselves
modulate the expression of several miRNAs. Moreover,
miRNAs can as well regulate oestrogen receptor levels
[70,71]. None of the miRNAs described in the literature
related to oestrogen appears to be deregulated in the
BCVY profile presented. The different profile obtained
between BCVY and normal breast samples from young
women (with similar oestrogen levels) supports the idea
that the intrinsic levels of oestrogen are not responsible
of the miRNA deregulation.Early pregnancies and lactation are considered pro-
tector factors in BC and they could bias the comparison
between young and older woman. In our series, older
women in general have early age at first birth and still
have developed breast cancer, while in the young women
we have representation of both circumstances and all of
them fall in the same miRNA profile, highlighting young
age as the main leading factor of the profiling.
Mammary density is the strongest risk factor for non-
familial breast cancer among women, apart from older
age. Young women present denser breast tissue in mam-
mographies, which makes more difficult the diagnosis.
In addition, differences in normal breast microenviron-
ment seem to exert an influence on the behavior of breast
cancer cells in premenopausal women [72]. A recent mo-
lecular profiling study performed on adjacent tissue of
breast tumours, classifies extratumoral stromal microenvi-
ronments into two primary gene expression phenotypes
(Active and Inactive). The Active subtype has high expres-
sion of genes involved in activation of fibrosis, cellular
movement, increased TWIST expression, and positive ex-
pression of TGF-b signatures. Inactive phenotype is over-
represented by samples from young women and according
to Perez and cols, means higher levels of cell adhesion and
cell–cell contact genes [73,74]. The miRNA profile pre-
sented in our study pointed out to pathways also related
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of implicated miRNAs indicates a downregulation of the
targeted genes and therefore, stroma that correlates with
young and denser breast tissue is not the driver in our
deregulated miRNAs signature.
Finally, BMI (Body Mass Index) has been recently
related to BC risk and survival. In older women higher
BMI results in elevated risk of developing BC, while in
young women is a protector factor [75]. In our study the
mean value of BMI in BCVY is within normal ranges,
which makes difficult any speculation about its role in
BCVY.
In our study all patients but one are confirmed to be
of European Caucasian ethnicity. This implies that our
miRNA profile might not be representative of other gen-
etic backgrounds such as African descent, where exists a
higher proportion of breast cancer in young women. On
the other side, the study has been performed in a very
homogeneous population which reinforces the conclu-
sions obtained and we encourage the replication of our
findings in other ethnicity breast cancer collections.
Conclusions
Our results suggest that breast cancer in young patients
appears to be a different biological entity. Previously
published works and in silico enrichment analyses of the
miRNAs deregulated in young women suggest that tar-
geted genes involved in proliferation pathways, cell ad-
hesion, apoptosis, extracellular matrix and cell motility,
deregulation of these pathways may lead to more aggres-
sive, proliferative and metastatic tumour phenotypes. A
more detailed analysis of those miRNA significantly up-
or downregulated could guide both to the establishment
of a different hypothesis about the potential molecular
mechanisms involved in the carcinogenesis and to identify
more specific therapeutic targets in this particular set
of patients.
Additional files
Additional file 1: Haematoxylin and eosin staining images from
tissue samples used in the present study. Sections from FFPE tissue
blocks stained with haematoxylin and eosin. A, B: correspond to samples
from normal healthy mammary tissue. C, D: represent the mammary
tumour from young women. E, F: show breast tumour tissue obtained
from older women.
Additional file 2: List and p-values of miRNAs significantly
differences in expression between BCVY and BC. Significantly
different expressed miRNAs among two sample groups: young women in
breast cancer (BCVY, younger than 35 years old) and older than 65 years
women with breast cancer (BC). P-values and FDR p-values (corrected for
Benjamini and Hochberg’s False Discovery Rate for multiple comparisons)
were obtained performing a t-test with 200000 permutations.
Nomenclature of miRNAs belong to miRBase v.15.
Additional file 3: List and p-values of miRNAs significantly
differences in expression between BCVY and BC. Significantly
different expressed miRNAs among two sample groups: young women inbreast cancer (BCVY, younger than 35 years old) and older than 65 years
women with breast cancer (BC), headed by Age FDR (from Additional
file 1: Table S1), the association of miRNA was further analyzed correcting
for tumour characteristics (grade, tumour size, Ki67 and nodal status) to
assess whether there are any confounding factor. FDR p-values are
corrected for Benjamini and Hochberg’s False Discovery Rate for multiple
comparisons and were obtained performing a t-test with 200000
permutations. Nomenclature of miRNAs belong to miRBase v.15.
Additional file 4: MicroRNA selected for this study from miRNAs
significantly associated with young women’s breast cancer in
discovery set and its validation. Clusters were constructed using
Average hierarchical clustering method. Statistics of the discovery set
were calculated via t-test. FDR stands for False Discovery rate multitesting
corrected p-value. Only miRNAs remarked in bold were validated on an
independent set of patients. Fold change of the validation set were
calculated using ΔΔCt method and p-values were estimated via ANOVA
test comparing the age groups and adjusted for multiple testing using
Tukey’s method. Bold denotes significant associated results in validation set.
Additional file 5: Putative pathways enriched with the miRNAs
included in the sub-node 15 and 63. Code between brackets refers to
the pathway code on KEGG, hsa means homo sapiens. FDR refers to
p-value adjusted by False Discovery Rate. 20 miRNAs were included in a
pathway enrichment analysis and obtained the genes union results.
Additional file 6: Information about miRNAs selected for validation.
Information of the miRNAs selected for validation, including 3p or 5p
form (3’ or 5’), MIMAT ID, family and sequence of the mature miRNA.
“*” refers to the minor form of the miRNA, according to miRBase v.15
nomenclature.
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